Cargando…

1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)

BACKGROUND: TB is the most common opportunistic infection in PLWH. IPT is recommended for PLWH in endemic areas and for those with LTBI diagnosed by Quantiferon gold-in-tube (QGIT) or tuberculin skin test (TST) in other areas. We report on the performance of QGIT and TST in pregnant WLWH who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinberg, Adriana, Aaron, Lisa, Montepiedra, Grace, Sterling, Timothy, Chaktoura, Nahida, Browning, Renee, Mmbaga, Blandina T, Vhembo, Tichaona, Nandkumar. Naik, Shilpa, Pahwa, Savita, Mathad, Jyoti S, LaCourse, Sylvia, McCarthy, Katie S, Bradford, Sarah, Costello, Diane G, Zimmer, Bonnie, Flore Pierre, Marie, Gupta, Amita, Theron, Gerhard B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808683/
http://dx.doi.org/10.1093/ofid/ofz360.1251
_version_ 1783461794750136320
author Weinberg, Adriana
Aaron, Lisa
Montepiedra, Grace
Sterling, Timothy
Chaktoura, Nahida
Browning, Renee
Mmbaga, Blandina T
Vhembo, Tichaona
Nandkumar. Naik, Shilpa
Pahwa, Savita
Mathad, Jyoti S
LaCourse, Sylvia
McCarthy, Katie S
Bradford, Sarah
Costello, Diane G
Zimmer, Bonnie
Flore Pierre, Marie
Gupta, Amita
Theron, Gerhard B
author_facet Weinberg, Adriana
Aaron, Lisa
Montepiedra, Grace
Sterling, Timothy
Chaktoura, Nahida
Browning, Renee
Mmbaga, Blandina T
Vhembo, Tichaona
Nandkumar. Naik, Shilpa
Pahwa, Savita
Mathad, Jyoti S
LaCourse, Sylvia
McCarthy, Katie S
Bradford, Sarah
Costello, Diane G
Zimmer, Bonnie
Flore Pierre, Marie
Gupta, Amita
Theron, Gerhard B
author_sort Weinberg, Adriana
collection PubMed
description BACKGROUND: TB is the most common opportunistic infection in PLWH. IPT is recommended for PLWH in endemic areas and for those with LTBI diagnosed by Quantiferon gold-in-tube (QGIT) or tuberculin skin test (TST) in other areas. We report on the performance of QGIT and TST in pregnant WLWH who received IPT antepartum (AP) or postpartum (PP). METHODS: WLWH participating in IMPAACT P1078, a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT AP vs. PP, were tested by QGIT at entry (14–34 weeks gestation) and by QGIT and TST at delivery (L&D) and 44 weeks PP. Serial QGIT positivity was assessed by logistic regression using generalized estimating equations. RESULTS: Among 944 women with study entry mean (SD) of 29 (6) years of age, 521 (245) CD4+ cells/µL, on ART, including 63% with undetectable HIV plasma RNA, 284/944 (30%) were QGIT+ AP, 215/862 (25%) at L&D and 246/764 (32%) PP (P < 0.001), while 127 (15%) were TST+ at L&D and 126 (17%) PP. QGIT was more likely positive than TST at L&D (Odds ratio = 4.3; 95% CI = 2.8–6.8) and PP (6.4; 3.9–10.7; P < 0.001). QGIT and TST agreement coefficients (95% CI) were 0.4 (0.3–0.5) at L&D and 0.5 (0.4–0.5) PP. Among women QGIT+ AP, 59 (24%) reverted to QGIT- or indeterminate at L&D. However, 37 (63%) reverters recovered QGIT+ results PP, suggesting transient suppression of IFNg responses during pregnancy. Responses to the mitogen-positive QGIT kit control were absent in 60 (7%) women AP, 116 (16%) at L&D, but only 3 (0.4%) PP (P < 0.01), supporting the notion of transient immune suppression during pregnancy. Among women QGIT- AP, 33 (7%) converted to QGIT+ PP. Among AP QGIT+ women, 24 (11%) reverted to QGIT- PP after finishing IPT. None of the results differed between treatment arms (P ≥ 0.13). CONCLUSION: In WLWH on ART, the loss of IFNγ responses to TB antigen and mitogen in pregnancy decreased the diagnostic value of QGIT. TST was similar at L&D and PP but was less sensitive than QGIT. QGIT conversions likely resulted from a combination of PP immune reconstitution and new TB infections. QGIT reversions might represent a change in TB-specific immunity in response to IPT. Reversions have been reported in adults without HIV after treatment of active TB. The clinical significance of QGIT reversions in PLWH needs further investigation. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6808683
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68086832019-10-28 1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT) Weinberg, Adriana Aaron, Lisa Montepiedra, Grace Sterling, Timothy Chaktoura, Nahida Browning, Renee Mmbaga, Blandina T Vhembo, Tichaona Nandkumar. Naik, Shilpa Pahwa, Savita Mathad, Jyoti S LaCourse, Sylvia McCarthy, Katie S Bradford, Sarah Costello, Diane G Zimmer, Bonnie Flore Pierre, Marie Gupta, Amita Theron, Gerhard B Open Forum Infect Dis Abstracts BACKGROUND: TB is the most common opportunistic infection in PLWH. IPT is recommended for PLWH in endemic areas and for those with LTBI diagnosed by Quantiferon gold-in-tube (QGIT) or tuberculin skin test (TST) in other areas. We report on the performance of QGIT and TST in pregnant WLWH who received IPT antepartum (AP) or postpartum (PP). METHODS: WLWH participating in IMPAACT P1078, a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT AP vs. PP, were tested by QGIT at entry (14–34 weeks gestation) and by QGIT and TST at delivery (L&D) and 44 weeks PP. Serial QGIT positivity was assessed by logistic regression using generalized estimating equations. RESULTS: Among 944 women with study entry mean (SD) of 29 (6) years of age, 521 (245) CD4+ cells/µL, on ART, including 63% with undetectable HIV plasma RNA, 284/944 (30%) were QGIT+ AP, 215/862 (25%) at L&D and 246/764 (32%) PP (P < 0.001), while 127 (15%) were TST+ at L&D and 126 (17%) PP. QGIT was more likely positive than TST at L&D (Odds ratio = 4.3; 95% CI = 2.8–6.8) and PP (6.4; 3.9–10.7; P < 0.001). QGIT and TST agreement coefficients (95% CI) were 0.4 (0.3–0.5) at L&D and 0.5 (0.4–0.5) PP. Among women QGIT+ AP, 59 (24%) reverted to QGIT- or indeterminate at L&D. However, 37 (63%) reverters recovered QGIT+ results PP, suggesting transient suppression of IFNg responses during pregnancy. Responses to the mitogen-positive QGIT kit control were absent in 60 (7%) women AP, 116 (16%) at L&D, but only 3 (0.4%) PP (P < 0.01), supporting the notion of transient immune suppression during pregnancy. Among women QGIT- AP, 33 (7%) converted to QGIT+ PP. Among AP QGIT+ women, 24 (11%) reverted to QGIT- PP after finishing IPT. None of the results differed between treatment arms (P ≥ 0.13). CONCLUSION: In WLWH on ART, the loss of IFNγ responses to TB antigen and mitogen in pregnancy decreased the diagnostic value of QGIT. TST was similar at L&D and PP but was less sensitive than QGIT. QGIT conversions likely resulted from a combination of PP immune reconstitution and new TB infections. QGIT reversions might represent a change in TB-specific immunity in response to IPT. Reversions have been reported in adults without HIV after treatment of active TB. The clinical significance of QGIT reversions in PLWH needs further investigation. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808683/ http://dx.doi.org/10.1093/ofid/ofz360.1251 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Weinberg, Adriana
Aaron, Lisa
Montepiedra, Grace
Sterling, Timothy
Chaktoura, Nahida
Browning, Renee
Mmbaga, Blandina T
Vhembo, Tichaona
Nandkumar. Naik, Shilpa
Pahwa, Savita
Mathad, Jyoti S
LaCourse, Sylvia
McCarthy, Katie S
Bradford, Sarah
Costello, Diane G
Zimmer, Bonnie
Flore Pierre, Marie
Gupta, Amita
Theron, Gerhard B
1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)
title 1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)
title_full 1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)
title_fullStr 1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)
title_full_unstemmed 1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)
title_short 1387. Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)
title_sort 1387. women living with hiv (wlwh) lose ifnγ responses diagnostic of latent tb infection (ltbi) during pregnancy and after inh prophylactic treatment (ipt)
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808683/
http://dx.doi.org/10.1093/ofid/ofz360.1251
work_keys_str_mv AT weinbergadriana 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT aaronlisa 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT montepiedragrace 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT sterlingtimothy 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT chaktouranahida 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT browningrenee 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT mmbagablandinat 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT vhembotichaona 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT nandkumarnaikshilpa 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT pahwasavita 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT mathadjyotis 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT lacoursesylvia 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT mccarthykaties 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT bradfordsarah 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT costellodianeg 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT zimmerbonnie 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT florepierremarie 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT guptaamita 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt
AT therongerhardb 1387womenlivingwithhivwlwhloseifngresponsesdiagnosticoflatenttbinfectionltbiduringpregnancyandafterinhprophylactictreatmentipt